Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637349 | 0.93 | LRRK2 (0.45) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2637024 | 0.92 | LRRK2 (0.45) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL15226876 | 0.92 | PTK2 (0.52) | LRRK2PTK2ALK | |
| SCHEMBL2029264 | 0.90 | LRRK2 (0.47) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2032989 | 0.89 | LRRK2 (0.44) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2637440 | 0.88 | LRRK2 (0.43) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2637790 | 0.88 | PTK2 (0.50) | LRRK2PTK2ALK | |
| SCHEMBL2029269 | 0.87 | PTK2 (0.48) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL2637085 | 0.87 | PTK2 (0.51) | LRRK2PTK2ALK | |
| SCHEMBL2637631 | 0.86 | EGFR (0.44) | LRRK2PTK2ALKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | LRRK2 854/4885PTK2 2/4885JAK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.